Marketplace reaction to the COVID-19 pandemic drove nearly 9% sales growth for Bausch Health Companies Inc. consumer health products but also put a $65m dent in its income from slow Rx and medtech sales due to mass postponements of ocular and dermatologic surgeries.
The Canadian firm on 7 May reported first-quarter global sales of Lumify eye drops, PreserVision supplements and other consumer health...







